-
Azathramycin A: A Translational TB Strategy
2026-08-24
Azathramycin A offers a research lens on ribosome-directed antibacterial activity, degradation-aware assay design, and site-of-action pharmacology. This thought-leadership guide translates macrolide exposure–response principles into a disciplined framework for Mycobacterium tuberculosis studies without overstating evidence from other disease models.
-
Epoxomicin: A Proteasome Probe for Viral Inflammation
2026-08-24
Epoxomicin is an irreversible proteasome inhibitor that can do more than block protein turnover: it helps distinguish viral control of RIPK3 degradation from downstream proteolytic execution. This article translates a pivotal orthopoxvirus study into practical assay logic for ubiquitin-proteasome pathway research.
-
TH287 Radiosensitizes CRPC Cells to Ionizing Radiation
2026-08-23
A 2026 study found that TH287, an MTH1 inhibitor, enhanced ionizing-radiation responses in PC-3 and DU-145 castration-resistant prostate cancer cells. The strongest effect occurred when radiation was delivered 12 hours after TH287 exposure, with increased apoptosis, caspase-3 changes, and cell-cycle arrest supporting a timing-sensitive radiosensitization strategy.
-
Calpain Inhibitor I, ALLN: Workflow Guide
2026-08-22
Calpain Inhibitor I, ALLN (SKU A2602) provides a practical way to inhibit calpain I, calpain II, and selected cathepsins in controlled apoptosis, inflammation, and ischemia-reperfusion studies. It is intended for research workflows only; concentrations, exposure conditions, and in vivo dosing must be established for each model rather than inferred from biochemical potency values.
-
Lipo3K Transfection Reagent for Smart ASO Assays
2026-08-22
Explore how Lipo3K Transfection Reagent can support rigorous nucleic acid assay design, from difficult cell models to pH-responsive antisense oligonucleotide studies. This guide connects delivery performance with cargo structure, controls, timing, and interpretation.
-
HBsAg Hijacks TBK1 to Suppress Interferon
2026-08-21
A 2025 Cell Death and Disease study identifies TBK1 as a central host target through which hepatitis B surface antigen suppresses type I interferon signaling while promoting incomplete autophagy. The work connects HBsAg-dependent TBK1 dimerization, disrupted TBK1–IRF3 signaling, p62 phosphorylation, and impaired autophagosome–lysosome fusion to HBV replication and possible viral persistence.
-
Deferoxamine Mesylate: Iron-Chelation Research Guide
2026-08-20
Deferoxamine mesylate is an iron-chelating agent that forms ferrioxamine and reduces the pool of chemically available iron. Research evidence supports its use in iron metabolism, oxidative stress protection, HIF-1α stabilization, and model-specific tissue or tumor studies, while the TCF25 study provides a separate framework for interpreting iron-linked lysosomal stress.
-
Cy5 maleimide (non-sulfonated): Protocol Guide
2026-08-20
Cy5 maleimide (non-sulfonated) is a thiol-reactive labeling reagent for attaching a Cy5 fluorophore to accessible cysteine residues in peptides and proteins. It is appropriate for site-directed fluorescence workflows but should not be selected for targets without accessible thiols or for protocols that require a water-soluble labeling reagent without an organic co-solvent.
-
2X HyperFusion High-Fidelity Master Mix Guide
2026-08-19
2X HyperFusion High-Fidelity Master Mix is a ready-to-use PCR formulation for high accuracy DNA amplification, cloning, and other workflows that benefit from proofreading. Its HyperFusion high-fidelity DNA polymerase combines processivity with 3′→5′ exonuclease proofreading and generates blunt-ended products, while the cited colorectal cancer study provides a separate biological context for accurate molecular construct preparation.
-
Syringin in RCC: EGFR/PI3K/Akt and Sunitinib
2026-08-19
A 2024 Journal of Functional Foods study identifies Syringin as an experimental inhibitor of renal cell carcinoma behavior and a potential enhancer of sunitinib response. By combining network pharmacology, molecular docking, bioinformatics, cell-based assays, and Western blotting, the authors connect these effects to EGFR/PI3K/Akt signaling and apoptosis.
-
DFO for Latent Fingerprint Detection
2026-08-18
DFO combines amino-acid reactivity with fluorescence to improve latent print visualization on paper and other porous evidence. This practical guide covers solvent selection, workflow controls, imaging optimization, troubleshooting, and the critical distinction between forensic DFO and deferoxamine mesylate used in biomedical research.
-
Mitochondrial IRF3 in Pulmonary Fibrosis
2026-08-18
A 2026 Cellular Signalling study identifies mitochondrial IRF3 as a mechanistic link between cGAS-STING activation, defective PINK1-associated mitophagy, and ferroptosis in alveolar epithelial cells. Its bleomycin-induced mouse model and TGF-β-stimulated A549 experiments suggest that limiting IRF3 mitochondrial translocation may offer a more specific strategy for pulmonary fibrosis research than targeting inflammation alone.
-
Luminescent ATP Detection Assay Kit for GBM
2026-08-17
Use the Luminescent ATP Detection Assay Kit for rapid, sensitive ATP profiling in glioblastoma cells, tissue lysates, and metabolic perturbation studies. Its gentle lysis workflow, 1 nM–10 μM linear range, and downstream protein compatibility make it a practical complement to PXDN–LDHA mechanistic experiments.
-
Rifampin for Mechanistic Bacterial Assays
2026-08-17
Rifampin is a rifamycin antibiotic for dissecting bacterial transcription, resistance evolution, and synthetic circuits. This article presents a causal assay framework that separates immediate RNA polymerase inhibition from later adaptive responses.
-
DiscoveryProbe FDA-approved Drug Library Workflow
2026-08-16
Learn how to use a clinically annotated compound collection for mechanism-led screening, secretion assays, and translational validation. This workflow emphasizes disease-relevant phenotypes, orthogonal confirmation, and practical troubleshooting rather than viability-only hit calling.